DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2032)

Diabetic Nephropathy | Landscape & Forecast | Disease Landscape & Forecast

Diabetic Nephropathy | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Diabetic nephropathy (DN), also referred as diabetic kidney disease, is a common complication of diabetes. Current standard of care fails to halt the frequent progression of DN to kidney disease and, ultimately, kidney failure—a condition associated with severe morbidity / mortality and high costs to patients, payers, and healthcare systems. As a result, key opinion leaders indicate that efficacious therapies for DN are a major unmet need, and they weigh in on the anticipated nephroprotective effects that endothelin receptor antagonists, mineralocorticoid receptor antagonists, and SGLT-2 inhibitor may offer. These therapies represent the first potentially disease-modifying therapies, should they prove efficacious and safe. The increasing prevalence of DN, exacerbated by the dynamics between clinicians seeking to prescribe new, premium-priced therapies and payers seeking to control costs among an already expensive population, will help shape the changing DN market over the next ten years.

Questions answered

  • Will the inclusion of cardiovascular end points in the clinical trials for select therapies be a competitive advantage once commercially available?
  • How do KOLs view the different mechanisms of action of the different therapies in early- and late-phase clinical development?
  • What are the greatest remaining unmet needs in DN? Which drugs in development will fulfill these unmet needs?
  • What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • June 2019
      • March 2019
    • Executive Summary
      • Key Findings
    • Market Outlook
      • Key Findings
        • Expert Insight
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Diabetic Nephropathy?
        • What Factors Are Constraining the Market for Diabetic Nephropathy?
      • Drug Class-Specific Trends
        • Sodium-Glucose Co-Transporter 2 Inhibitors
        • Antidiabetics
        • Mineralocorticoid Receptor Antagonists
        • Antihypertensives
    • Forecast
    • Etiology and Pathophysiology
      • Key Findings
        • Expert Insight
      • Pathophysiology
        • Pathophysiology
      • Natural History of Diabetic Nephropathy
        • Natural History
      • Risk Factors
        • Risk Factors
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
        • Expert Insight
      • Epidemiology Populations
        • Total Prevalent Cases of Diabetic Nephropathy
        • Diagnosed Prevalent Cases of Diabetic Nephropathy
        • Drug-Treated Cases of Diabetic Nephropathy
    • Current Treatment Overview
      • Key Findings
        • Expert Insight
      • Treatment Goals
        • Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • Renin-Angiotensin-Aldosterone System Inhibitors
        • Other Antihypertensive Drug Classes
        • SGLT-2 Inhibitors for Type 2 Diabetes
        • Other Antidiabetics
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Diabetic Nephropathy
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Diabetic Nephropathy
        • Sodium-Glucose Co-Transporter 2 Inhibitors
        • Mineralocorticoid Receptor Antagonists
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Diabetic Nephropathy/Diabetic Kidney Disease
      • Key Discontinuations and Failures in Diabetic Nephropathy
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Diabetic Nephropathy Bibliography

Already a Client? Log in to access this report.

  • Pub Date: June 2019
  • Author(s): Shreya Saxena, MBA; Seth Kuranz, MPH
  • Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.

  • Seth joined DRG as an Associate Epidemiologist in ; Seth holds an from Boston University and a in Anthropology from Arizona State ; Currently Seth is pursuing a doctorate in Epidemiology from Boston University School of Public ; Prior to joining DRG, Seth served as the coordinator of a community coalition implementing substance abuse prevention ; For the past three years Seth worked as a research assistant examining misuse of alcohol among University students in Mexico City contributing to data analysis and publication of the research ;    

Purchase Report

Recent reports:
You may also be interested in: